Eli Lilly and Company vs Merck & Co., Inc.

Full side-by-side comparison — 2026

Data as of May 20, 2026 · Updated automatically

10
LLY Wins
0
Tie
9
MRK Wins

LLY

Price USD 1043.47
P/E Ratio 35.5x
Div Yield 0.0065%
Beta 0.48
Sector Health Care

MRK

Price USD 115.79
P/E Ratio 31.7x
Div Yield 0.0298%
Beta 0.20
Sector Health Care

Price Overview

Metric LLY MRK
Current Price 1043.47 115.79
Previous Close 1018.87 113.00

Valuation

Metric LLY MRK
Trailing P/E 35.51 31.71
Forward P/E 22.53 11.77
Price / Book 28.67 6.06
Price / Sales 12.35 4.23
EV / EBITDA 25.84 10.89

Dividends & Income

Metric LLY MRK
Dividend Yield 0.0065% 0.0298%
Dividend Rate (Annual) 6.46 3.32
5-Year Avg Yield 1.11% 2.95%
Payout Ratio 0.2210% 0.9212%

Risk & Financial Health

Metric LLY MRK
Beta (Volatility) 0.48 0.20
Debt / Equity 139.02 106.94
Quick Ratio 0.72 0.70
Current Ratio 1.50 1.30

Growth & Profitability

Metric LLY MRK
Revenue Growth 0.5550% 0.0490%
Earnings Growth 1.6990% -0.1930%
Return on Equity 1.0746% 0.1894%
Revenue / Share 80.61 26.42
Trailing EPS 28.19 3.55
Forward EPS 44.44 9.57

Analyst Targets

Metric LLY MRK
Analyst Mean Target 1210.00 129.74
Analyst High Target 1500.00 150.00
Analyst Low Target 850.00 100.00

Bottom Line: LLY vs MRK

Eli Lilly and Company (LLY) leads on 10 of 19 comparable metrics.

Eli Lilly and Company is the stronger pick for growth investors, while Merck & Co., Inc. may appeal to value investors.

Eli Lilly and Company has a higher Earnings Growth (169.90% vs -19.30%), which indicates profits are growing more quickly
Eli Lilly and Company has a higher Revenue Growth (55.50% vs 4.90%), which indicates the business is expanding faster
Eli Lilly and Company has a higher Trailing EPS (28.19 vs 3.55), which means higher earnings per share over the last 12 months

This comparison is based on publicly available financial data and is for informational purposes only. It is not investment advice. Past performance does not guarantee future results.

LLY Eli Lilly and Company

Best for Growth Investors
• Higher Revenue Growth: 55.50%
• Higher Earnings Growth: 169.90%
• Higher Return on Equity: 107.46%

MRK Merck & Co., Inc.

Best for Value Investors
• Lower Trailing P/E: 31.71
• Lower Forward P/E: 11.77
• Lower Price / Book: 6.06
Best for Income Investors
• Higher Dividend Yield: 2.98%
• Higher 5-Year Avg Yield: 2.95%

Analyst Upside / Downside

LLY
+16.0%
MRK
+12.0%

Based on analyst mean price targets. Estimates are not guaranteed and may not reflect future performance.

About These Companies

Eli Lilly and Company (LLY)

Health Care · United States · NYQ

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza …

View LLY details →

Merck & Co., Inc. (MRK)

Health Care · United States · NYQ

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, …

View MRK details →

Frequently Asked Questions

Which has a better dividend yield, LLY or MRK?
Merck & Co., Inc. currently has the higher dividend yield. Eli Lilly and Company (LLY) yields 0.65% while Merck & Co., Inc. (MRK) yields 2.98%. Past dividends do not guarantee future payments.
Which is more volatile, LLY or MRK?
Eli Lilly and Company is more volatile based on beta. Eli Lilly and Company has a beta of 0.48 and Merck & Co., Inc. has a beta of 0.20. A beta above 1.0 means higher volatility than the overall market.
Which is cheaper by P/E ratio, LLY or MRK?
Merck & Co., Inc. has the lower trailing P/E ratio. Eli Lilly and Company trades at 35.5x earnings while Merck & Co., Inc. trades at 31.7x. A lower P/E may suggest better relative value, but could also reflect lower growth expectations.
Which has more analyst upside, LLY or MRK?
Based on mean analyst price targets, Eli Lilly and Company has more upside potential. Eli Lilly and Company has +16.0% upside and Merck & Co., Inc. has +12.0% upside from current prices. Analyst estimates are not guaranteed.
Can I track both LLY and MRK in one portfolio?
Yes. AllInvestView lets you add both Eli Lilly and Company and Merck & Co., Inc. to the same portfolio and monitor price changes, dividends, total return, and allocation — completely free.

Track LLY and MRK in Your Portfolio

Add both to AllInvestView and compare their real-time performance, dividends, and gain/loss side by side.

Start Free Portfolio

Related Comparisons

Health Care Peers

Stock Pages